Company Number: 14655282

Analysis Date: 2025-07-29 18:14 UTC

Financial Health Assessment Report for GALASKO CARDIAC SERVICES LIMITED

---

1. Financial Health Score: B

Explanation:
For a company incorporated recently (Feb 2023) and reporting its first financial period, GALASKO CARDIAC SERVICES LIMITED demonstrates a solid initial financial footing with positive net current assets and healthy cash reserves. The absence of debt beyond short-term liabilities and positive retained earnings are good signs. However, the limited operating history and relatively small capital base constrain a higher grade at this stage.

---

2. Key Vital Signs

Metric	Value (£)	Interpretation
Cash at Bank	70,403	Strong cash position indicating good liquidity ("healthy cash flow").
Current Assets	74,832	Includes cash and debtors; good short-term asset base.
Current Liabilities	20,288	Includes tax liabilities and accrued expenses; manageable short-term debt ("no signs of distress in immediate liabilities").
Net Current Assets	54,544	Positive working capital, indicating ability to cover short-term obligations comfortably.
Shareholders’ Funds	54,544	Equity base equal to net assets, showing no long-term liabilities—"strong balance sheet foundation".
Called-up Share Capital	200	Low initial capital, typical for a start-up but limits buffer for shocks.
Retained Earnings	54,344	Accumulated profits or reserves, positive sign of value creation despite short timeframe.

---

3. Diagnosis

GALASKO CARDIAC SERVICES LIMITED exhibits the financial equivalent of a patient with a strong pulse and no immediate symptoms of distress. The company's "vital signs" reveal a healthy liquidity position with cash covering more than three times its current liabilities, signaling strong short-term financial health. The positive net current assets and shareholders' funds show the company is well-capitalized relative to its size and has not taken on long-term debt, which reduces financial risk.

However, as a newly established entity with a short operating history, it is akin to a young patient who appears healthy but whose long-term prognosis depends on sustaining cash flow and growing revenues. The presence of director advances (loans from Dr. Galasko) of £4,428 is small and manageable, but reliance on director financing should be monitored.

The company's operation in the general medical practice sector (SIC 86210) typically involves steady revenue streams but can be sensitive to regulatory changes and reimbursement rates, which must be factored into ongoing health monitoring.

---

4. Recommendations

• Maintain Strong Liquidity: Continue to monitor cash flow closely to preserve the healthy cash reserves, ensuring the company can meet short-term liabilities with ease ("healthy blood circulation").
• Build Capital Base: Consider gradually increasing share capital or retained earnings through reinvestment of profits to create a stronger financial cushion ("building muscle strength").
• Revenue Diversification: Expand service offerings or client base to reduce reliance on a narrow revenue stream, reducing vulnerability to sector-specific shocks ("enhancing immune response").
• Manage Tax Liabilities Proactively: The current tax creditor balance (£19,011) is significant relative to liabilities; ensure timely tax payments to avoid penalties.
• Director Loan Transparency: Maintain clear records and repayment plans for director advances to avoid governance concerns and ensure personal funds do not mask operational cash flow issues.
• Plan for Growth: As the company matures, invest in systems for regular financial forecasting and scenario planning to anticipate potential financial stressors ("preventative health check-ups").
• Compliance and Reporting: Keep up with filing deadlines and regulatory requirements to avoid penalties and maintain corporate good standing ("staying up to date with vaccinations").

---